Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clint A Stalnecker

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Autophagy|February 26, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>Daniel J Klionsky, Amal Kamal Abdel-Aziz, Sara Abdelfatah, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Autophagy|February 26, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>Daniel J Klionsky, Amal Kamal Abdel-Aziz, Sara Abdelfatah, et al.
Pageof 3